San Diego biotech says new type 1 diabetes studies raise hopes for 'functional cure'
A century ago, type 1 diabetes was a death sentence. But San Diego biotech ViaCyte says two studies published this week show the company is getting closer to what it calls a “functional cure” for the disease.
Read More: San Diego biotech says new type 1 diabetes studies raise hopes for 'functional cure'
Source: Virgin Islands Daily News
